Friday, 18 November 2011
US Federal Trade Commission (FTC) Chairman Jon Leibowitz says fighting against “pay-for-delay” settlements in pharmaceutical patent litigation will continue to be a priority for the commission should he be given a second term as chairman.
Wednesday, 26 October 2011
The number of so-called “pay-for-delay” patent settlements between branded and generic drug makers declined last year, but potentially anti-competitive settlements continue to be pervasive in the pharmaceutical industry, the US Federal Trade Commission says.
Wednesday, 21 September 2011
Thomas Rosch, a commissioner at the US Federal Trade Commission, has asked a key US lawmaker to deny an attempt to attach pay-for-delay patent settlement reform to a larger, unrelated debt reduction bill.
Tuesday, 20 September 2011
The chairman of the US Federal Trade Commission has pledged support for a component of President Barack Obama’s deficit reduction plan that would make it harder for branded drug companies to settle patent litigation by paying their generic rivals.
Thursday, 07 July 2011
The number of patent settlements in Europe’s pharmaceutical industry that could potentially violate antitrust law continues to decline, according to European Commission statistics released yesterday.
Wednesday, 25 May 2011
The US Federal Trade Commission (FTC) has petitioned the Third Circuit Court of Appeals in support of class action plaintiffs that are challenging pay-for-delay agreements in the pharmaceutical industry.
Premium Article - Wednesday, 12 January 2011
A group of 32 state attorneys general have told the US Supreme Court that they need clarification on the legality of pay-for-delay pharmaceutical settlements - which only the high court can provide.
Premium Article - Friday, 12 November 2010
Several pharmaceutical companies have told a US appeals court that the Federal Trade Commission’s (FTC) attempt to overturn a failed pay-for-delay prosecution should be thrown out.
Premium Article - Wednesday, 22 September 2010
Jon Leibowitz, chairman of the US Federal Trade Commission, offered his assessment of the FTC’s performance over the past 12 months, at the Georgetown Law fourth annual Global Antitrust Enforcement Symposium. Emily Gray in Washington, DC
Premium Article - Thursday, 29 July 2010
Lawmakers this week questioned US Federal Trade Commission Chairman Jon Leibowitz over accusations that the commission committed misconduct in the course of a reverse payment settlement pharmaceutical investigation.
Premium Article - Friday, 23 July 2010
The US Federal Trade Commission has fought back against charges that it acted improperly in investigating an alleged pay-for-delay pharmaceutical deal by disclosing confidential business secrets and attempting to broker a behind-the-scenes deal between two drug makers.
Premium Article - Wednesday, 07 July 2010
The US House of Representatives has approved measures that would limit the circumstances when branded drug companies can enter into settlement agreements with potential generic challengers.
Premium Article - Tuesday, 06 July 2010
Featured In: July 2010 (Vol. 13 Iss. 7)
Just weeks after the US passed its comprehensive health-care reform law, GCR sat down with some of the top health-care antitrust practitioners in the world to discuss how antitrust law would affect the future of health care in both the US and Europe. Ron Knox met with the panel at the offices of White & Case LLP in Washington, DC, to hear their views on how antitrust enforcement would help shape health-care reform
Premium Article - Thursday, 14 January 2010
The US Federal Trade Commission yesterday published a study showing that the lack of access to generic drugs caused by reverse settlement payments in the pharmaceutical industry could cost US consumers as much as US$35 billion over 10 years.
Premium Article - Wednesday, 28 October 2009
The US Federal Trade Commission says that German drugmaker Boehringer Ingelheim has refused to respond to subpoenas sent as part of an investigation of whether the company violated section 5 of the FTC Act when it paid a rival to end patent litigation.
Back to top
